207 related articles for article (PubMed ID: 21190562)
1. PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis.
Zhang K; Waxman DJ
Mol Cancer; 2010 Dec; 9():319. PubMed ID: 21190562
[TBL] [Abstract][Full Text] [Related]
2. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells.
Li H; Chen X; Calhoun-Davis T; Claypool K; Tang DG
Cancer Res; 2008 Mar; 68(6):1820-5. PubMed ID: 18339862
[TBL] [Abstract][Full Text] [Related]
3. Enhanced regulation of cell cycle and suppression of osteoblast differentiation molecular signatures by prostate cancer stem-like holoclones.
Gallagher MF; Salley Y; Spillane CD; Ffrench B; El Baruni S; Blacksheilds G; Smyth P; Martin C; Sheils O; Watson W; O'Leary JJ
J Clin Pathol; 2015 Sep; 68(9):692-702. PubMed ID: 26038242
[TBL] [Abstract][Full Text] [Related]
4. H460 non-small cell lung cancer stem-like holoclones yield tumors with increased vascularity.
Manley E; Waxman DJ
Cancer Lett; 2014 Apr; 346(1):63-73. PubMed ID: 24334139
[TBL] [Abstract][Full Text] [Related]
5. Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
Zhang K; Waxman DJ
Mol Cancer Ther; 2013 May; 12(5):787-98. PubMed ID: 23635653
[TBL] [Abstract][Full Text] [Related]
6. The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells.
Gruber M; Handle F; Culig Z
Prostate; 2020 Feb; 80(3):267-273. PubMed ID: 31834633
[TBL] [Abstract][Full Text] [Related]
7. Holoclone forming cells from pancreatic cancer cells enrich tumor initiating cells and represent a novel model for study of cancer stem cells.
Tan L; Sui X; Deng H; Ding M
PLoS One; 2011; 6(8):e23383. PubMed ID: 21826251
[TBL] [Abstract][Full Text] [Related]
8. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells.
Bae KM; Su Z; Frye C; McClellan S; Allan RW; Andrejewski JT; Kelley V; Jorgensen M; Steindler DA; Vieweg J; Siemann DW
J Urol; 2010 May; 183(5):2045-53. PubMed ID: 20303530
[TBL] [Abstract][Full Text] [Related]
9. Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells.
Shimada K; Anai S; Fujii T; Tanaka N; Fujimoto K; Konishi N
J Pathol; 2013 Dec; 231(4):495-504. PubMed ID: 24549646
[TBL] [Abstract][Full Text] [Related]
10. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.
Fernandez A; Udagawa T; Schwesinger C; Beecken W; Achilles-Gerte E; McDonnell T; D'Amato R
J Natl Cancer Inst; 2001 Feb; 93(3):208-13. PubMed ID: 11158189
[TBL] [Abstract][Full Text] [Related]
11. Implication of expression of Nanog in prostate cancer cells and their stem cells.
Gong C; Liao H; Guo F; Qin L; Qi J
J Huazhong Univ Sci Technolog Med Sci; 2012 Apr; 32(2):242-246. PubMed ID: 22528228
[TBL] [Abstract][Full Text] [Related]
12. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Dozmorov MG; Azzarello JT; Wren JD; Fung KM; Yang Q; Davis JS; Hurst RE; Culkin DJ; Penning TM; Lin HK
BMC Cancer; 2010 Dec; 10():672. PubMed ID: 21134280
[TBL] [Abstract][Full Text] [Related]
13. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
Calvo A; Xiao N; Kang J; Best CJ; Leiva I; Emmert-Buck MR; Jorcyk C; Green JE
Cancer Res; 2002 Sep; 62(18):5325-35. PubMed ID: 12235003
[TBL] [Abstract][Full Text] [Related]
14. AZGP1 deficiency promotes angiogenesis in prostate cancer.
Wen RM; Qiu Z; Marti GEW; Peterson EE; Marques FJG; Bermudez A; Wei Y; Nolley R; Lam N; Polasko AL; Chiu CL; Zhang D; Cho S; Karageorgos GM; McDonough E; Chadwick C; Ginty F; Jung KJ; Machiraju R; Mallick P; Crowley L; Pollack JR; Zhao H; Pitteri SJ; Brooks JD
J Transl Med; 2024 Apr; 22(1):383. PubMed ID: 38659028
[TBL] [Abstract][Full Text] [Related]
15. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells.
Patrawala L; Calhoun-Davis T; Schneider-Broussard R; Tang DG
Cancer Res; 2007 Jul; 67(14):6796-805. PubMed ID: 17638891
[TBL] [Abstract][Full Text] [Related]
16. Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).
Reddy KRK; Dasari C; Duscharla D; Supriya B; Ram NS; Surekha MV; Kumar JM; Ummanni R
Angiogenesis; 2018 Feb; 21(1):79-94. PubMed ID: 29150732
[TBL] [Abstract][Full Text] [Related]
17. Spheres derived from the human SN12C renal cell carcinoma cell line are enriched in tumor initiating cells.
Zhang Y; Sun B; Zhao X; Sun H; Cui W; Liu Z; Yao X; Dong X
J Exp Clin Cancer Res; 2016 Oct; 35(1):163. PubMed ID: 27756344
[TBL] [Abstract][Full Text] [Related]
18. Genomic analysis of prostate cancer stem cells isolated from a highly metastatic cell line.
Rowehl RA; Crawford H; Dufour A; Ju J; Botchkina GI
Cancer Genomics Proteomics; 2008; 5(6):301-10. PubMed ID: 19287071
[TBL] [Abstract][Full Text] [Related]
19. Functional evidence implicating S100P in prostate cancer progression.
Basu GD; Azorsa DO; Kiefer JA; Rojas AM; Tuzmen S; Barrett MT; Trent JM; Kallioniemi O; Mousses S
Int J Cancer; 2008 Jul; 123(2):330-339. PubMed ID: 18452169
[TBL] [Abstract][Full Text] [Related]
20. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.
Hurt EM; Kawasaki BT; Klarmann GJ; Thomas SB; Farrar WL
Br J Cancer; 2008 Feb; 98(4):756-65. PubMed ID: 18268494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
